

June 3, 2019

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

Code: **532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

Code: **CADILAHC**

Re.: Notification


Dear Sir / Madam,

We hereby inform that the USFDA inspected the Company's manufacturing facilities located at St. Louis, MO, USA of Neshor Pharmaceuticals (USA) LLC (100% subsidiary of Zydus Pharmaceuticals USA), from 13<sup>th</sup> May to 31<sup>st</sup> May, 2019. The inspection concluded with 3 observations at one facility and 8 observations at the other facility of Neshor Pharmaceuticals with a recommendation for 'Voluntary Action Indicated (VAI)'.

This was a product specific pre-approval inspection with general cGMP and there were no Data Integrity (DI) related observations. The Company is confident of addressing these observations and responding to the USFDA at the earliest.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

For, **CADILA HEALTHCARE LIMITED**



**DHAVAL N. SONI**  
**COMPANY SECRETARY**

